Novo Nordisk CEO Mike Doustdar announced the company is seeking external acquisitions to bolster its weight-loss drug pipeline. The strategy targets assets that can complement or surpass internal developments to fill existing portfolio gaps.
This shift follows a significant stock price decline after a capital markets day failed to reassure investors. Doustdar acknowledged the need to rebuild market confidence, admitting the company has previously overpromised and underdelivered.
Pressure to diversify is mounting as key patents for Wegovy and Ozempic expire in the early 2030s. The company is specifically scouting for opportunities in obesity-related sectors, including cardiovascular disease treatments.